MODIFICATION
L -- Genome-Wide Association Study and Prospective Gene-Expression Study
- Notice Date
- 8/31/2004
- Notice Type
- Modification
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, Nat'l Institute of Diabetes, Digestive, & Kidney Diseases, 2 Democracy Plaza, Suite 700W 6707 Democracy Blvd., MSC 5455, Bethesda, MD, 20892-5455
- ZIP Code
- 20892-5455
- Solicitation Number
- NIH-NIDDK-04-315
- Response Due
- 9/10/2004
- Archive Date
- 9/25/2004
- Point of Contact
- Patricia Haun, Purchasing Agent, Phone (301) 594-8855, Fax (301) 480-4226,
- E-Mail Address
-
haunp@extra.niddk.nih.gov
- Description
- This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation number is NIH-NIDDK-04-315, and is issued as a Request for Quotation (RFQ). The solicitation/contract will include all applicable provisions and clauses in effect through Federal Acquisition Circular 2001-24. The North American Industry Classification (NAICS) Code is 541380 and the business size standard is $6.0 M. However, this solicitation is not set aside for small business. This acquisition is being conducted using Simplified Acquisition Procedures in accordance with FAR Part 13. The National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), has a requirement for a Genome-Wide Association Study and Prospective Gene-Expression Study Tasks to be performed for the Genome-Wide Association Study: Genotype DNA samples, to be provided by NIH, from approximately 975 participants in Gila River Indian Community study. Genotyping should include approximately 100,000 SNPs covering the entire human genome. Data will be provided to NIH in a computer-readable format. Technical requirements for the Genome-Wide Association Study: 1) The NIH will provide samples of DNA extracted from peripheral blood lymphocytes or cultured cells from study participants. The Contractor shall propose the quantity of DNA required per sample. 2) The Contractor shall propose the method for genotyping, including internal quality control measures, for approval by the NIH. In addition to the Contractor’s internal quality control procedures, the NIH will include in the samples an unspecified number of blinded duplicate samples for quality control analysis by the NIH. 3) The Contractor shall provide the NIH with a computer-readable data set containing genotype results for each SNP typed, identified by each individual DNA sample submitted. Contractor shall specify, for NIH approval, the data base program or format for data transfer. Receivables for the Genome-Wide Association Study: It is anticipated that all typing will be performed in one batch and that all results will be reported together. Items to be reported are: 1) Electronic data base containing genotyping results from all samples. 2) Report of any internal quality control results obtained by the Contractor. Tasks to be performed for the Prospective Gene-Expression Study: mRNA extraction, hybridization, and micro-array of skeletal muscle tissue, to be provided by NIH, from approximately 120 participants in the Gila River Indian Community study. The micro-array studies should characterize the expression of approximately 50,000 genes per sample.. Data will be provided to NIH in a computer-readable format. All surplus muscle tissue and mRNA must be preserved and returned to NIH in a condition suitable for subsequent analyses. Technical Requirements for the Prospective Gene-Expression Study: 1) The Contractor shall propose the quantity of tissue required per sample. The NIH will provide frozen samples of skeletal muscle tissue that approximate this quantity. 2) The Contractor shall extract mRNA from the supplied tissue. 3) The Contractor shall propose the method for gene-expression analysis for approval by the NIH, including internal quality control measures, for approval by the NIH. In addition to the Contractor’s internal quality control procedures, the NIH will include in the samples an unspecified number of blinded duplicate samples for quality control analysis by the NIH. 4) The Contractor shall provide the NIH with a computer-readable dataset containing genome-wide expression results, identified by each individual mRNA sample submitted. Contractor shall specify, for NIH approval, the database program or format for data transfer. Receivable for the Prospective Gene-Expression Study: It is anticipated that micro-array analyses will be performed in one batch, and that all results will be reported together. Items to be reported are: 1) Electronic database containing comprehensive gene-expression results from all samples. 2) Report of any internal quality control results obtained by the Contractor. The offeror must include a completed copy of the provision of FAR Clause 52.212-3, Offeror Representations and Certifications – Commercial Items with its offer. The provisions of FAR Clause 52.212-4, Contract Terms and Conditions – Commercial Items, applies to this acquisition. The addenda to the clause reads as follows: The offeror must include in their quotation, the unit price, the list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. The FAR Clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders – Commercial Items – Deviation for Simplified Acquisitions, applies to this acquisition. The clauses are available in full text at http://www.arnet.gov/far. Interested vendors capable of furnishing the government with the item specified in this synopsis should submit their quotation to the below address. Quotations will be due fifteen (15) calendar days from the publication date of this synopsis or September 13, 2004. The quotation must reference “Solicitation number” NIH-NIDDK-04-315. All responsible sources may submit a quotation, which if timely received, shall be considered by the agency. Quotations must be submitted in writing to the National Institute of Diabetes and Digestive and Kidney Diseases 6707 Democracy Blvd., Room 774C, Bethesda, Maryland 20817, Attention: Patricia Haun. Faxed copies will not be accepted. NOTE: THIS NOTICE WAS NOT POSTED TO WWW.FEDBIZOPPS.GOV ON THE DATE INDICATED IN THE NOTICE ITSELF (31-AUG-2004); HOWEVER, IT DID APPEAR IN THE FEDBIZOPPS FTP FEED ON THIS DATE. PLEASE CONTACT fbo.support@gsa.gov REGARDING THIS ISSUE.
- Web Link
-
Link to FedBizOpps document.
(http://www.eps.gov/spg/HHS/NIH/NIDDKD/NIH-NIDDK-04-315/listing.html)
- Place of Performance
- Address: Phoenix, AZ
- Record
- SN00662825-F 20040902/040901040826 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |